Distribution of disulfonated and tetrasulfonated aluminum phthalocyanine between malignant and host cell populations of a murine fibrosarcoma

Korbelik, Mladen

doi:10.1016/1011-1344(93)80148-3

Cited by 43 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Murine squamous cell carcinoma SCCVII (Suit et al, 1985) and mammary sarcoma EMT6 (Rockwell et al, 1972) were maintained in syngeneic C3H/HeN and BALB/c mice respectively, as described in detail elsewhere (Korbelik, 1993;Korbelik and Krosl, 1996). For tumour implantation, 1 x 106 tumour cells were inoculated subcutaneously in the lower dorsal region of 8-to 11-weekold female mice.…”

Section: Materials and Methods Tumour Models And Treatmentsmentioning

confidence: 99%

The value of serum α-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy

Korbelik

Naraparaju²,

Yamamoto³

1998

Br J Cancer

View full text Add to dashboard Cite

Summary Serum activity of ax-N-acetylgalactosaminidase (NaGalase), the extracellular matrix-degrading enzyme that appears to be produced exclusively by cancer cells, was measured in mice bearing SCCVII tumours (squamous cell carcinoma). The NaGalase levels in these mice increased with time of tumour growth and were directly proportional to tumour burden. After exposure of SCCVII tumours to a single X-ray dose of 20 Gy, the serum NaGalase levels gradually decreased during the first 10 days after treatment (to approximately one-third of the initial value) and then began to increase. The decrease in serum NaGalase activity was more rapid after the treatment of SCCVII and EMT6 tumours by photodynamic therapy (PDT) and was dependent on the PDT dose. The treatments (based on photosensitizers Photofrin or mTHPC) that were fully curative resulted in the reduction of NaGalase activity to background levels within 2 or 3 days after PDT. A slower decrease in NaGalase activity was found after PDT treatments that attain an initial tumour ablation but are not fully curative. The regrowth of PDT-treated SCCVII tumours was preceded by an increase in serum NaGalase levels, which was detected as early as 8 days before the visible tumour reappearance. These findings ascertain the validity of serum NaGalase measurement for the assessment of tumour response to different treatments and support the concept that the NaGalase measurement could serve as a diagnostic and prognostic index that might allow oncologists to design the dosage or nature of treatment.

show abstract

Section: Materials and Methods Tumour Models And Treatmentsmentioning

confidence: 99%

The value of serum α-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy

Korbelik

Naraparaju²,

Yamamoto³

1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…On the other hand, at different dose klvels these same agents cause immune stimulation (Ngwenya and Yamamoto, 1986;Yamamoto and Ngwenya, 1987 (Korbelik, 1993). This is a weakly immunogenic tumour which orig ted spontaneously in the abdominal wall of a C3H mouse (Olive et al, 1985).…”

mentioning

confidence: 99%

Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy

Krosl¹,

Korbelik²,

Dougherty³

1995

Br J Cancer

195

124

View full text Add to dashboard Cite

“…Tumours excised at 3 days after g-inulin only treatment, control untreated tumours, and tissue materials collected from the tumour sites at 3 days after PDT and PDT plus g-inulin treatments (there was no sign of tumour left at that time with these two treatment groups) were subjected to standard enzymatic disaggregation procedure (Korbelik, 1993). Single-cell suspensions obtained in this way were stained with FITC-conjugated rat-anti-mouse CD107a (sc-19992) and PE-conjugated rat anti-mouse CD8 (both from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), plus PerCP-Cy5.5-conjugated rat anti-mouse panleukocyte marker CD45 (Pharmingen, BD Biosciences, Mississauga, Ontario, Canada).…”

Section: Flow Cytometrymentioning

confidence: 99%

Potentiation of photodynamic therapy of cancer by complement: the effect of γ-inulin

Korbelik

Cooper

2006

Br J Cancer

View full text Add to dashboard Cite

Host response elicited by photodynamic therapy (PDT) of cancerous lesions is a critical contributor to the clinical outcome, and complement system has emerged as its important element. Amplification of complement action was shown to improve tumour PDT response. In search of a clinically relevant complement activator for use as a PDT adjuvant, this study focused on g-inulin and examined its effects on PDT response of mouse tumours. Intralesional g-inulin (0.1 mg mouse À1 ) delivered immediately after PDT rivaled zymosan (potent classical complement activator) in delaying the recurrence of B16BL6 melanomas. This effect of g-inulin was further enhanced by IFN-g pretreatment. Tumour C3 protein levels, already elevated after individual PDT or g-inulin treatments, increased much higher after their combination. With fibrosarcomas MCA205 and FsaR, adjuvant g-inulin proved highly effective in reducing recurrence rates following PDT using four different photosensitisers (BPD, ce6, Photofrin, and mTHPC). At 3 days after PDT plus g-inulin treatment, over 50% of cells found at the tumour site were CTLs engaged in killing specific targets via perforingranzyme pathway. This study demonstrates that g-inulin is highly effective PDT adjuvant and suggests that by amplifying the activation of complement system, this agent potentiates the development of CTL-mediated immunity against PDT-treated tumours.

show abstract

Distribution of disulfonated and tetrasulfonated aluminum phthalocyanine between malignant and host cell populations of a murine fibrosarcoma

Cited by 43 publications

References 12 publications

The value of serum α-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy

The value of serum α-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy

Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy

Potentiation of photodynamic therapy of cancer by complement: the effect of γ-inulin

Contact Info

Product

Resources

About